Pfizer begins phase 2b/3 trial of PF-06651600 to treat alopecia areata

Pfizer begins phase 2b/3 trial of PF-06651600 to treat alopecia areata

Submitted by admin on January 4, 2019 - 9:12am
Source: 
Pharmaceutical Business Review
News Tags: 
Pfizer
clinical trials
PF-06651600
JAK3 inhibitors
alopecia areata
Headline: 
Pfizer begins phase 2b/3 trial of PF-06651600 to treat alopecia areata
snippet: 


Pfizer has started a phase 2b/3 clinical trial of PF-06651600, an oral JAK3 inhibitor to treat patients with moderate to severe alopecia areata.

Do Not Allow Advertisers to Use My Personal information